Merck to present first Phase 3 data for intismeran, sac-TMT at ESMO 2026

Merck announced first-time pivotal Phase 3 results from three oncology trials will be presented at ESMO 2026 Presidential Symposia. INTerpath-001 showed intismeran autogene plus KEYTRUDA improved recurrence-free and distant metastasis-free survival versus KEYTRUDA alone in resected stage IIB-IV melanoma. TroFuse-005 is the first Phase 3 trial of a TROP2-directed ADC to show overall survival and progression-free survival benefit in advanced endometrial cancer. KEYNOTE-C93 supports first-line KEYTRUDA monotherapy in dMMR endometrial cancer. Merck will host an investor event Oct. 26.